MCID: PTT006
MIFTS: 55

Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pituitary Adenoma

MalaCards integrated aliases for Pituitary Adenoma:

Name: Pituitary Adenoma 12 58 29 54 15 70
Pituitary Neoplasms 44 70
Pituitary Adenomas 36 15
Adenoma of the Pituitary Gland 12
Pituitary Gland Adenoma 17
Adenoma, Pituitary 39

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:3829
KEGG 36 H01102
MeSH 44 D010911
NCIt 50 C3329
SNOMED-CT 67 154621002
ICD10 via Orphanet 33 D35.2
UMLS via Orphanet 71 C0032000
Orphanet 58 ORPHA99408
UMLS 70 C0032000 C0032019

Summaries for Pituitary Adenoma

KEGG : 36 Pituitary adenomas are an important and frequently occurring form of intracranial tumor. They are usually benign but can give rise to severe clinical syndromes due to hormonal excess, or to visual/cranial disturbances due to mass effect. The tumor can be clinically nonfunctioning or hormone secreting. Among the latter, prolactin (PRL) and growth hormone (GH)-secreting adenomas are the most common. The majority of pituitary adenomas arise sporadically, although a subset occurs as component tumors of well-characterized familial cancer syndromes, such as multiple endocrine neoplasia type 1 (MEN1), Carney complex (CNC), and MEN1-like syndrome (MEN4).

MalaCards based summary : Pituitary Adenoma, also known as pituitary neoplasms, is related to functionless pituitary adenoma and thyroid carcinoma. An important gene associated with Pituitary Adenoma is MIR15A (MicroRNA 15a), and among its related pathways/superpathways are Transcriptional misregulation in cancer and ErbB signaling pathway. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and brain.

Disease Ontology : 12 A pituitary gland benign neoplasm that derives from glandular epithelial cells.

Wikipedia : 73 Pituitary adenomas are tumors that occur in the pituitary gland. Pituitary adenomas are generally... more...

Related Diseases for Pituitary Adenoma

Diseases in the Pituitary Adenoma family:

Pituitary Adenoma 1, Multiple Types Pituitary Adenoma 5, Multiple Types
Pituitary Adenoma 3, Multiple Types

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 705)
# Related Disease Score Top Affiliating Genes
1 functionless pituitary adenoma 32.4 MEG3 HOTAIR
2 thyroid carcinoma 31.0 MALAT1 HOTAIR H19
3 thyroid cancer, nonmedullary, 1 30.8 MEG3 MALAT1 HOTAIR H19
4 glioma 30.5 MIR15A MEG3 MALAT1 HOTAIR H19 CCAT2
5 osteogenic sarcoma 30.4 MEG3 MALAT1 HOTAIR H19 CCAT2
6 high grade glioma 30.4 MEG3 MALAT1 HOTAIR H19
7 lung cancer susceptibility 3 30.0 MIR15A MEG3 MALAT1 HOTAIR H19
8 myeloma, multiple 30.0 MIRLET7E MIR15A MEG3 MALAT1 HOTAIR H19
9 kidney cancer 29.9 MIR15A MEG3 MALAT1 HOTAIR H19
10 nasopharyngeal carcinoma 29.7 MIR26B MIR223 MIR212 MEG3 MALAT1 HOTAIR
11 ovarian disease 29.7 MIRLET7A1 MIR24-1 MIR223 MIR132
12 glioblastoma 29.6 MIR24-1 MIR149 MIR132 MIR128-1 MEG3 MALAT1
13 renal cell carcinoma, nonpapillary 29.6 MIRLET7A1 MIR212 MIR15A MIR149 MALAT1 HOTAIR
14 leukemia, chronic lymphocytic 29.6 MIR24-1 MIR223 MIR16-1 MIR15A MIR132
15 parkinson disease, late-onset 29.5 MIR24-1 MIR212 MIR132 MALAT1 HOTAIR H19
16 gastrointestinal system disease 29.4 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR15A MIR149
17 reproductive system disease 29.4 MIRLET7A1 MIR24-1 MIR223 MIR15A MIR149 MIR132
18 leukemia, acute myeloid 29.2 MIRLET7E MIR223 MIR212 MIR15A MIR128-1 MEG3
19 central nervous system disease 29.1 MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212 MIR15A
20 prostate disease 29.1 MIRLET7A1 MIR24-1 MIR223 MIR15A MIR149 MEG3
21 melanoma 29.1 MIRLET7E MIR15A MIR149 MIR128-1 MEG3 MALAT1
22 gastric cancer 29.0 MIR24-1 MIR223 MIR16-1 MIR149 MEG3 MALAT1
23 pancreatic cancer 28.6 MIR24-1 MIR223 MIR212 MIR16-1 MIR15A MIR132
24 prostate cancer 28.6 MIRLET7A1 MIR26B MIR223 MIR16-1 MIR15A MIR149
25 nervous system disease 28.4 MIRLET7E MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212
26 hepatocellular carcinoma 27.2 MIRLET7E MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212
27 pituitary adenoma 1, multiple types 11.9
28 pituitary adenoma, prolactin-secreting 11.8
29 acth-secreting pituitary adenoma 11.8
30 pituitary adenoma 2, growth hormone-secreting 11.8
31 pituitary adenoma 5, multiple types 11.7
32 familial isolated pituitary adenoma 11.7
33 pituitary adenoma 3, multiple types 11.7
34 pituitary adenoma 4, acth-secreting 11.6
35 acromegaly 11.6
36 functioning pituitary adenoma 11.6
37 adenoma 11.5
38 growth hormone secreting pituitary adenoma 11.5
39 non-functioning pituitary adenoma 11.4
40 hypopituitarism 11.3
41 tsh producing pituitary tumor 11.3
42 mixed functioning pituitary adenoma 11.2
43 somatomammotropinoma 11.2
44 multiple endocrine neoplasia 11.2
45 carney complex variant 11.1
46 acroleukopathy, symmetric 11.1
47 silent pituitary adenoma 11.1
48 gastrointestinal defects and immunodeficiency syndrome 11.1
49 null pituitary adenoma 11.1
50 acth-independent macronodular adrenal hyperplasia 11.1

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Cefdinir Approved Phase 4 91832-40-5 6915944
6
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
7
Cefazolin Approved Phase 4 25953-19-9 656510 33255
8
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
9
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
10
Sulfamethoxazole Approved Phase 4 723-46-6 5329
11
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
12
Metformin Approved Phase 4 657-24-9 14219 4091
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
15
Morphine Approved, Investigational Phase 4 57-27-2 5288826
16
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
17
Ibuprofen Approved Phase 4 15687-27-1 3672
18
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
19
Cabergoline Approved Phase 4 81409-90-7 54746
20
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
21
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
22
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
23
Lactitol Approved, Investigational Phase 4 585-86-4 157355
24
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
26
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
27
lanreotide Approved Phase 4 108736-35-2
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29 Pharmaceutical Solutions Phase 4
30 Hydrocortisone 17-butyrate 21-propionate Phase 4
31 Hydrocortisone hemisuccinate Phase 4
32 Anti-Bacterial Agents Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Vitamin B Complex Phase 4
35 Folate Phase 4
36 Vitamin B9 Phase 4
37 Anti-Infective Agents Phase 4
38 Folic Acid Antagonists Phase 4
39 Cephalosporins Phase 4
40 Antiparasitic Agents Phase 4
41 cefuroxime axetil Phase 4
42 Antimalarials Phase 4
43 Antiprotozoal Agents Phase 4
44 Clindamycin phosphate Phase 4
45 Clindamycin palmitate Phase 4
46 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
47 Cytochrome P-450 Enzyme Inhibitors Phase 4
48 Antirheumatic Agents Phase 4
49 Narcotics Phase 4
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Unknown status NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
4 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
5 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
6 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
7 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
8 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
9 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
10 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
11 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
12 The Effects of Infraorbital Nerve Block With Dexmedetomidine Added to Bupivacaine on Fentanyl Requirement During Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor: Prospective Randomized Double Blinded Control Study Not yet recruiting NCT04785222 Phase 4 dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
13 A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity Terminated NCT01861717 Phase 4 lanreotide
14 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Unknown status NCT02419664 Phase 3
15 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
16 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
17 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
18 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
19 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
20 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
21 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
22 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
23 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
24 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
25 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
26 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Active, not recruiting NCT03621280 Phase 3 Levoketoconazole
27 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
28 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
29 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
30 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Unknown status NCT01849484 Phase 2
31 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
32 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
33 Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC Unknown status NCT02749227 Phase 2 Pasireotide LAR
34 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
35 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
36 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
37 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
38 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
39 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
40 Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
41 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Recruiting NCT03930771 Phase 2 Capecitabine;Temozolomide
42 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Recruiting NCT04339751 Phase 2 Vorinostat
43 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
44 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
45 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
46 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab;Nivolumab
47 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
48 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
49 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Terminated NCT01915303 Phase 2 Pasireotide with or without cabergoline
50 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Octreotide
Octreotide Acetate

Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

# Genetic test Affiliating Genes
1 Pituitary Adenoma 29

Anatomical Context for Pituitary Adenoma

MalaCards organs/tissues related to Pituitary Adenoma:

40
Pituitary, Thyroid, Brain, Kidney, Breast, Bone, Liver

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 7752)
# Title Authors PMID Year
1
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 47 61
17111382 2007
2
Multiple endocrine neoplasia type 1-associated cystic pancreatic endocrine neoplasia and multifocal cholesterol granulomas. 54 61
20403035 2010
3
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. 54 61
20111911 2010
4
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 61 54
20106827 2010
5
Transcripts of PTTG and growth factors bFGF and IGF-1 are correlated in pituitary adenomas. 54 61
19472104 2010
6
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. 54 61
20150876 2010
7
No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. 54 61
19919817 2009
8
Acromegaly pathogenesis and treatment. 61 54
19884662 2009
9
Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. 61 54
19684062 2009
10
Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. 61 54
20045804 2009
11
Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. 54 61
19443539 2009
12
[Outcome of somatostatin analogue treatment in acromegaly]. 54 61
19617182 2009
13
Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event. 61 54
19356755 2009
14
The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability. 61 54
19366855 2009
15
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. 54 61
19223528 2009
16
GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. 61 54
19236640 2009
17
Combined acromegaly and subclinical Cushing disease related to high-molecular-weight adrenocorticotropic hormone. 61 54
18991502 2009
18
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. 61 54
19347192 2009
19
Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. 61 54
18840925 2009
20
Acromegaly accompanied by Turner syndrome with 47,XXX/45,X/46,XX mosaicism. 54 61
19293545 2009
21
Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. 61 54
19153518 2009
22
Pituitary adenoma stem cells. 54 61
19582428 2009
23
Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. 54 61
19169048 2008
24
Update on the treatment of pituitary adenomas: familial and genetic considerations. 54 61
19170361 2008
25
Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary. 61 54
18633321 2008
26
Large genomic deletions in AIP in pituitary adenoma predisposition. 54 61
18628514 2008
27
Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. 54 61
18410548 2008
28
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. 54 61
18698020 2008
29
Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis. 61 54
18620995 2008
30
Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. 61 54
18445999 2008
31
The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. 54 61
18381572 2008
32
Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells. 61 54
18367633 2008
33
Multiple Endocrine Neoplasia type 1. 61 54
18249304 2008
34
Molecular and trophic mechanisms of tumorigenesis. 61 54
18226729 2008
35
Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells. 54 61
18273074 2008
36
Effect of somatostatin on repair of ionizing radiation-induced DNA damage in pituitary adenoma cells GH3. 61 54
17552875 2008
37
Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. 61 54
19029774 2008
38
Misdiagnosis due to the hook effect in prolactin assay. 61 54
18685288 2008
39
Adrenomedullin expression in pituitary adenomas and nontumoral adenohypophyses. 54 61
17952853 2008
40
Expression of adrenocorticotropic hormone, prolactin and transcriptional factors in clinically nonfunctioning pituitary adenoma. 54 61
18079591 2007
41
Familial pituitary adenomas with a heterogeneous functional pattern: clinical and genetic features. 54 61
17993773 2007
42
The clinical, pathological, and genetic features of familial isolated pituitary adenomas. 61 54
17893250 2007
43
Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. 54 61
17893251 2007
44
No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. 61 54
17914118 2007
45
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. 61 54
17524029 2007
46
Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary. 61 54
17561883 2007
47
Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. 61 54
17420609 2007
48
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. 54 61
17244780 2007
49
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. 54 61
17413185 2007
50
The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. 61 54
17371465 2007

Variations for Pituitary Adenoma

Cosmic variations for Pituitary Adenoma:

9 (show top 50) (show all 59)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87132301 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 27
2 COSM148932717 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 27
3 COSM148932735 PIK3CA pituitary,NS,adenoma,PRL c.*153A>G p.? 3:179234230-179234230 27
4 COSM87132318 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 3:179234230-179234230 27
5 COSM101967380 HRAS pituitary,NS,carcinoma,PRL c.34G>C p.G12R 11:534289-534289 27
6 COSM101951743 HRAS pituitary,NS,carcinoma,PRL c.34G>C p.G12R 11:534289-534289 27
7 COSM101951679 HRAS pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 27
8 COSM101967337 HRAS pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 27
9 COSM105721467 HRAS pituitary,NS,adenoma,PRL c.35G>T p.G12V 11:534288-534288 27
10 COSM112988978 HRAS pituitary,NS,carcinoma,PRL c.34G>C p.G12R 11:534289-534289 27
11 COSM91331236 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 27
12 COSM112988917 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 27
13 COSM105721542 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 27
14 COSM91331304 HRAS pituitary,NS,carcinoma,PRL c.34G>C p.G12R 11:534289-534289 27
15 COSM93760866 GNAS pituitary,NS,adenoma,GH c.2530C>T p.R844C 20:58909365-58909365 27
16 COSM93630265 GNAS pituitary,NS,adenoma,GH-alpha SU c.*507C>T p.? 20:58909365-58909365 27
17 COSM87642925 GNAS pituitary,NS,adenoma,GH c.94-402C>T p.? 20:58909365-58909365 27
18 COSM93086636 GNAS pituitary,NS,adenoma,GH c.604C>T p.R202C 20:58909365-58909365 27
19 COSM93726285 GNAS pituitary,NS,adenoma,GH c.559C>T p.R187C 20:58909365-58909365 27
20 COSM93726301 GNAS pituitary,NS,adenoma,GH c.560G>A p.R187H 20:58909366-58909366 27
21 COSM85346237 GNAS pituitary,NS,adenoma,GH c.635A>T p.Q212L 20:58909541-58909541 27
22 COSM85345830 GNAS pituitary,NS,adenoma,GH c.556C>T p.R186C 20:58909365-58909365 27
23 COSM93779606 GNAS pituitary,NS,adenoma,GH c.2488C>T p.R830C 20:58909365-58909365 27
24 COSM89474843 GNAS pituitary,NS,adenoma,GH c.*504C>T p.? 20:58909365-58909365 27
25 COSM93702294 GNAS pituitary,NS,adenoma,GH c.680A>T p.Q227L 20:58909541-58909541 27
26 COSM93701960 GNAS pituitary,NS,adenoma,GH c.601C>T p.R201C 20:58909365-58909365 27
27 COSM85345852 GNAS pituitary,NS,adenoma,GH c.557G>A p.R186H 20:58909366-58909366 27
28 COSM87642939 GNAS pituitary,NS,adenoma,GH c.94-401G>A p.? 20:58909366-58909366 27
29 COSM93726636 GNAS pituitary,NS,adenoma,GH c.638A>T p.Q213L 20:58909541-58909541 27
30 COSM93726530 GNAS pituitary,NS,adenoma,GH c.559C>A p.R187S 20:58909365-58909365 27
31 COSM93086945 GNAS pituitary,NS,adenoma,GH c.683A>T p.Q228L 20:58909541-58909541 27
32 COSM93779631 GNAS pituitary,NS,adenoma,GH c.2489G>A p.R830H 20:58909366-58909366 27
33 COSM93779988 GNAS pituitary,NS,adenoma,GH c.2567A>T p.Q856L 20:58909541-58909541 27
34 COSM93780281 GNAS pituitary,NS,adenoma,GH c.2567A>G p.Q856R 20:58909541-58909541 27
35 COSM93761460 GNAS pituitary,NS,adenoma,GH c.2609A>T p.Q870L 20:58909541-58909541 27
36 COSM93630681 GNAS pituitary,NS,adenoma,GH c.*586A>T p.? 20:58909541-58909541 27
37 COSM87643126 GNAS pituitary,NS,adenoma,GH c.94-402C>A p.? 20:58909365-58909365 27
38 COSM93702186 GNAS pituitary,NS,adenoma,GH c.601C>A p.R201S 20:58909365-58909365 27
39 COSM93086649 GNAS pituitary,NS,adenoma,GH c.605G>A p.R202H 20:58909366-58909366 27
40 COSM93761837 GNAS pituitary,NS,adenoma,GH c.2609A>G p.Q870R 20:58909541-58909541 27
41 COSM85346567 GNAS pituitary,NS,adenoma,GH c.635A>G p.Q212R 20:58909541-58909541 27
42 COSM93760887 GNAS pituitary,NS,adenoma,GH c.2531G>A p.R844H 20:58909366-58909366 27
43 COSM93701978 GNAS pituitary,NS,adenoma,GH c.602G>A p.R201H 20:58909366-58909366 27
44 COSM89475152 GNAS pituitary,NS,adenoma,GH c.*504C>A p.? 20:58909365-58909365 27
45 COSM93726964 GNAS pituitary,NS,adenoma,GH c.638A>G p.Q213R 20:58909541-58909541 27
46 COSM89474878 GNAS pituitary,NS,adenoma,GH c.*505G>A p.? 20:58909366-58909366 27
47 COSM87643479 GNAS pituitary,NS,adenoma,GH c.94-226A>G p.? 20:58909541-58909541 27
48 COSM87643227 GNAS pituitary,NS,adenoma,GH c.94-226A>T p.? 20:58909541-58909541 27
49 COSM93086861 GNAS pituitary,NS,adenoma,GH c.604C>A p.R202S 20:58909365-58909365 27
50 COSM93631069 GNAS pituitary,NS,adenoma,GH c.*586A>G p.? 20:58909541-58909541 27

Copy number variations for Pituitary Adenoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

Pathways related to Pituitary Adenoma according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 ErbB signaling pathway hsa04012
3 Cell cycle hsa04110
4 Apoptosis hsa04210
5 Insulin signaling pathway hsa04910

Pathways related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 MIRLET7E MIRLET7A1 MIR26B MIR223 MIR16-1 MIR15A
2 11.61 MIR138-2 MIR136 MIR132
3 11.28 MIR26B MIR212 MIR136 MIR132 MIR128-1
4 10.77 MIRLET7E MIRLET7A1
5 10.23 MEG3 HOTAIR

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.43 MIRLET7A1 MIR26B MIR24-1 MIR16-1 MIR15A MIR103A2
2 extracellular space GO:0005615 9.4 MIRLET7E MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.74 MIR16-1 MIR15A MIR138-2
2 negative regulation of interleukin-6 production GO:0032715 9.73 MIRLET7E MIR149 MIR132
3 negative regulation of angiogenesis GO:0016525 9.73 MIR24-1 MIR212 MIR16-1 MIR15A
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.71 MIR16-1 MIR15A MIR138-2
5 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.69 MIR16-1 MIR15A MIR149
6 negative regulation of blood vessel endothelial cell migration GO:0043537 9.65 MIR24-1 MIR212 MIR132
7 negative regulation of inflammatory response GO:0050728 9.65 MIR223 MIR16-1 MIR15A MIR149 MIR138-2
8 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.63 MIR223 MIR149 MIR132
9 negative regulation of vascular endothelial cell proliferation GO:1905563 9.62 MIR24-1 MIR132
10 negative regulation of peptidyl-serine phosphorylation GO:0033137 9.62 MIR212 MIR132
11 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.61 MIR16-1 MIR149
12 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR223 MIR15A
13 negative regulation of peptidyl-threonine phosphorylation GO:0010801 9.6 MIR15A MIR103A2
14 negative regulation of nitric oxide biosynthetic process GO:0045019 9.59 MIR212 MIR132
15 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.58 MIR24-1 H19
16 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.58 MIRLET7E MIRLET7A1
17 miRNA mediated inhibition of translation GO:0035278 9.56 MIRLET7E MIRLET7A1 MIR212 MIR16-1 MIR15A MIR138-2
18 negative regulation of STAT cascade GO:1904893 9.55 MIRLET7E MIR149
19 positive regulation of endothelial cell apoptotic process GO:2000353 9.54 MIR24-1 MIR15A MIR132
20 gene silencing by miRNA GO:0035195 9.53 MIRLET7E MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212
21 negative regulation of peptidyl-cysteine S-nitrosylation GO:1902083 9.52 MIR212 MIR132
22 negative regulation of nitric-oxide synthase activity GO:0051001 9.5 MIR212 MIR138-2 MIR132
23 negative regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000545 9.49 MIR16-1 MIR149
24 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.46 MIR24-1 MIR16-1 MIR15A MIR149
25 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.4 MIR16-1 MIR15A

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIRLET7E MIRLET7A1 MIR26B MIR24-1 MIR223 MIR212
2 mRNA 3'-UTR binding GO:0003730 9.26 MIR24-1 MIR16-1 MIR15A MIR103A2

Sources for Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....